All In Biotech

Drug Trial Radar · NCT02366143

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Sep 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,202 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,202

Actual

Start

Mar 31, 2015

Primary completion

Sep 13, 2019

Study completion Dec 7, 2020

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Feb 19, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, open-label study evaluated the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 \[PD-L1\] antibody) in combination with carboplatin+paclitaxel with or without bevacizumab compared with treatment with carboplatin+paclitaxel+bevacizumab in chemotherapy-naïve participants with Stage IV non-squamous NSCLC. Participants were randomized in a 1:1:1 ratio to Arm A (Atezolizumab+Carboplatin+Paclitaxel), Arm B (Atezolizumab+Carboplatin+Paclitaxel+Bevacizumab), or Arm C (Carboplatin+Paclitaxel+Bevacizumab).

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibodyDrug

    Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until loss of clinical benefit.

  • BevacizumabDrug

    Bevacizumab was administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, or death.

  • CarboplatinDrug

    Carboplatin was administered at area under the concentration-time curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.

  • PaclitaxelDrug

    Paclitaxel was administered as IV infusion at a dose of 200 milligrams per square meter (mg/m\^2) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT PopulationTime frame: Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)
  2. Overall Survival (OS) in Arm B Versus Arm C in ITT-WT PopulationTime frame: Baseline until death until data cut-off on 22 January 2018 (up to approximately 34 months)
  3. Overall Survival (OS) in Arm A Versus Arm C in ITT-WT PopulationTime frame: Baseline until death (up approximately 53 months)

Locations

240 sites in 26 countries. Site status is shown where the registry gives one.

  • Ironwood Cancer & Research Centers

    Chandler, Arizona

  • Arizona Oncology Associates

    Flagstaff, Arizona

  • Southern CA Permanente Med Grp

    Bellflower, California

  • Marin Cancer Care Inc

    Greenbrae, California

  • Scripps Health

    La Jolla, California

  • Chao Family Comprehensive Cancer Center UCI

    Orange, California

  • Rocky Mountain Cancer Center

    Denver, Colorado

  • Kaiser Permanente

    Lonetree, Colorado

  • Danbury Hospital

    Danbury, Connecticut

  • Yale Cancer Center

    New Haven, Connecticut

  • Holy Cross Hospital Inc

    Fort Lauderdale, Florida

  • Cancer Specialists of North Florida - Baptist South

    Jacksonville, Florida

  • Mount Sinai Medical Center

    Miami Beach, Florida

  • Hematology Oncology Associates of the Treasure Coast

    Port Saint Lucie, Florida

  • Piedmont Cancer Institute, PC

    Atlanta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • Univ of Chicago

    Chicago, Illinois

  • Ingalls Memorial Hospital

    Harvey, Illinois

  • Oncology Specialists, S.C.

    Park Ridge, Illinois

  • Hematology-Oncology; Associates of the Quad Cities

    Bettendorf, Iowa

  • Norton Cancer Institute

    Louisville, Kentucky

  • New England Cancer Specialists

    Scarborough, Maine

  • Mercy Medical Center

    Baltimore, Maryland

  • Regional Cancer Care Associates

    Bethesda, Maryland

  • Maryland Oncology Hematology, P.A.

    Columbia, Maryland

  • St. Joseph Mercy Health System

    Ann Arbor, Michigan

  • St. Luke's Regional Cancer Center

    Duluth, Minnesota

  • Park Nicolett - Frauenshuh Cancer Center

    Saint Louis Park, Minnesota

  • St. Luke's Cancer Institute

    Kansas City, Missouri

  • Missouri Baptist Medical Center

    St Louis, Missouri

  • Billings Clinic

    Billings, Montana

  • Montana Cancer Specialists

    Missoula, Montana

  • Comprehensive Cancer Centers of Nevada

    Henderson, Nevada

  • Summit Medical Group

    Berkeley Heights, New Jersey

  • Valley Hospital; Oncology Research

    Paramus, New Jersey

  • Regional Cancer Care Associates LLC

    Sewell, New Jersey

  • Maimonides Medical Center

    Brooklyn, New York

  • Montefiore Medical Center

    The Bronx, New York

  • First Health of the Carolinas

    Pinehurst, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

Showing 40 of 240 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.